What is Crohn's disease?

Crohn's disease is a chronic inflammatory bowel disease (IBD) where the immune system mistakenly attacks the gastrointestinal tract. Unlike ulcerative colitis, Crohn's can affect any part of the digestive tract from mouth to anus, and the inflammation penetrates the full thickness of the bowel wall. This transmural inflammation is what makes Crohn's prone to complications like fistulas, abscesses, and strictures.

What's the difference between Crohn's disease and ulcerative colitis?

Both are types of inflammatory bowel disease (IBD), but they differ in location, depth, and behavior. Crohn's: affects any part of GI tract, inflammation penetrates all bowel wall layers, can cause fistulas/abscesses/strictures, often has skip lesions. Ulcerative colitis: only affects colon/rectum, inflammation is superficial (mucosa only), continuous inflammation, higher risk of colon cancer.

Which biologic is best for Crohn's disease?

There is no single best biologic — choice depends on your disease location, severity, prior treatment history, insurance, and preference. Skyrizi (IL-23 inhibitor) shows the highest remission rates in head-to-head data. Stelara is effective with excellent long-term safety. Entyvio is gut-selective with favorable safety. Rinvoq is an oral option. Discuss with an IBD specialist.

Can Crohn's disease go into remission?

Yes. With modern biologics and targeted therapies, sustained clinical remission is achievable. Rates vary: Skyrizi achieves ~52% clinical remission at 52 weeks; Stelara ~34%; Entyvio ~26%; Rinvoq ~46%. Endoscopic healing (mucosal healing) is now the treatment target because it prevents complications.

How much do Crohn's biologics cost?

List prices for Crohn's biologics range from $60,000–$90,000/year. Manufacturer patient assistance programs can substantially reduce costs. Humira biosimilars are significantly cheaper. All major biologics have co-pay assistance for commercially insured patients. The Crohn's & Colitis Foundation (crohnscolitisfoundation.org) has financial assistance resources.

🫀

Crohn's Disease

Crohn's disease is a chronic inflammatory bowel disease that can affect any part of the GI tract — from mouth to anus — causing abdominal pain, severe diarrhea, fatigue, and malnutrition. Unlike ulcerative colitis, Crohn's inflammation penetrates all layers of the bowel wall and can create fistulas, abscesses, and strictures. Multiple biologics and small molecules now offer remission for patients who fail conventional therapy.

📊 Crohn's disease affects ~900,000 Americans. Onset typically occurs between ages 15–35, though it can occur at any age. Up to 70% of patients require surgery within 10 years of diagnosis without effective medical therapy.

Crohn's disease crohns IBD inflammatory bowel disease Stelara Crohns Skyrizi Crohns

Get Free Updates → View Treatments

👥 ~900,000 in US · Patients in US

🏥 Gastroenterology · Specialty

💊 5 available · FDA-approved drugs

FDA-Approved Treatments

Current approved therapies — what they are, who makes them, and what to ask your doctor.

Skyrizi

risankizumab · AbbVie

IL-23 Inhibitor (biologic)

FDA-approved for moderate-to-severe Crohn's disease (2022). IL-23 inhibitor — targets the p19 subunit of IL-23. Phase 3 trials showed ~45% clinical remission at 12 weeks induction, ~52% at 52 weeks maintenance.

💰 ~$85,000/year list price IV induction, then subcutaneous maintenance ✓ Patient Assist

Stelara

ustekinumab · Johnson & Johnson

IL-12/23 Inhibitor (biologic)

Approved for moderate-to-severe Crohn's disease (2016). Dual IL-12/23 blocker. Well-established safety profile with long-term data. Biosimilars (Wezlana, Selarsdi) now available at lower cost.

💰 ~$90,000/year list price IV induction, then subcutaneous every 8 weeks ✓ Patient Assist

Entyvio

vedolizumab · Takeda

Integrin Inhibitor (gut-selective biologic)

Gut-selective biologic — blocks α4β7 integrin. FDA-approved for Crohn's disease (2014). Favorable safety profile due to gut-restricted mechanism. Available as both IV and subcutaneous formulation.

💰 ~$60,000/year list price IV infusion or subcutaneous injection ✓ Patient Assist

Rinvoq

upadacitinib · AbbVie

JAK1 Inhibitor (oral)

FDA-approved for moderate-to-severe Crohn's disease (2023). First oral targeted therapy approved for Crohn's. JAK1-selective inhibitor — faster onset than biologics. ~39% clinical remission at 12 weeks, ~46% at 52 weeks.

💰 ~$65,000/year list price Oral daily pill ✓ Patient Assist

Humira

adalimumab · AbbVie (+ multiple biosimilars)

TNF Inhibitor (biologic)

First-line biologic for moderate-to-severe Crohn's disease. TNF-alpha inhibitor — well-established 20+ year track record. Multiple biosimilars now available at significantly lower cost.

💰 ~$25,000–$80,000/year (biosimilars vary) Subcutaneous injection ✓ Patient Assist

Community Feed

What patients and caregivers are saying about Crohn's Disease

View All →

Have something to share?

Join the Crohn's Disease community discussion on /pulse — share your experience, ask questions, or post research you've found.

Go to Pulse →

📋 Newly Diagnosed Guide

Newly diagnosed with Crohn's disease? What to do first.

🏥

1. Get to an IBD specialist (gastroenterologist with IBD expertise)

An IBD specialist will know the current biologic options, treat-to-target strategies, and navigate insurance. The Crohn's & Colitis Foundation (crohnscolitisfoundation.org) has a 'Find a Doctor' directory.

📊

2. Understand your disease extent and severity

Not all Crohn's is the same. Your GI needs to assess: which parts of the GI tract are involved, disease severity, presence of fistulas or strictures, perianal involvement, and inflammatory markers. Colonoscopy + imaging (CT or MR enterography) is typically needed for full disease mapping.

💊

3. Ask about early biologic therapy if your disease is moderate-to-severe

The old step-up approach is outdated for moderate-to-severe disease. Early biologic therapy prevents complications and improves long-term outcomes. Ask about Skyrizi, Stelara, or Entyvio as first-line advanced therapy.

🧪

4. Get a baseline colonoscopy to document mucosal inflammation

Mucosal healing is now the treatment target in Crohn's. You need a baseline to measure progress. Regular monitoring is needed to assess treatment response. Don't skip the colonoscopy even when you feel better.

💰

5. Engage patient assistance programs before worrying about cost

AbbVie (Skyrizi), J&J (Stelara), Takeda (Entyvio), and multiple biosimilar makers all have patient assistance programs. The Crohn's & Colitis Foundation has the IBD Help Center (888-694-8872) and financial assistance resources.

🔔 FREE ALERTS + PERSONALIZED UPDATES

Get Crohn's Disease Research Updates — Personalized to Your Situation

Weekly updates from NIH, FDA, and ClinicalTrials.gov. Tell us about your situation and we'll filter what's most relevant for you. Free. No spam.

Only email is required. By subscribing you agree to receive updates from My Sugar Pill. We never sell your data. Privacy policy.

Frequently Asked Questions

Real questions from patients and caregivers — answered in plain English.